Daniel Koller, BB Biotech's head of investment, discusses sector growth, innovation and the attractive valuations of fast-growing companies.
Partner insight At the beginning of 2016, biotech equities were unable to withstand the downward pressure that put financial markets around the globe into bear territory. More recently, movements...
Reducing volatility and maximising returns
Record organic asset growth
Global economic cycle is among the longest in history
Fixed income manager takes a more cautious approach
Duff & Phelps IM selected for real estate vehicle